Sankar D Navaneethan1, Sophia Zoungas2, M Luiza Caramori3, Juliana C N Chan4, Hiddo J L Heerspink5, Clint Hurst6, Adrian Liew7, Erin D Michos8, Wasiu A Olowu9, Tami Sadusky10, Nikhil Tandon11, Katherine R Tuttle12, Christoph Wanner13, Katy G Wilkens14, Lyubov Lytvyn15, Jonathan C Craig16, David J Tunnicliffe17, Martin Howell17, Marcello Tonelli18, Michael Cheung19, Amy Earley19, Peter Rossing20, Ian H de Boer21, Kamlesh Khunti22. 1. Section of Nephrology and Institute of Clinical and Translational Research, Baylor College of Medicine, and Michael E. DeBakey VA Medical Center, Houston, Texas (S.D.N.). 2. Monash University, School of Public Health and Preventive Medicine, Melbourne, Victoria, Australia (S.Z.). 3. University of Minnesota, Minneapolis, Minnesota (M.L.C.). 4. Hong Kong Institute of Diabetes and Obesity and Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Hong Kong, China (J.C.C.). 5. University of Groningen and University Medical Center, Groningen, the Netherlands (H.J.H.). 6. Houston, Texas (C.H.). 7. Mount Elizabeth Novena Hospital, Singapore (A.L.). 8. Johns Hopkins University School of Medicine, Baltimore, Maryland (E.D.M.). 9. Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Osun, Nigeria (W.A.O.). 10. Seattle, Washington (T.S.). 11. All India Institute of Medical Sciences, New Delhi, India (N.T.). 12. University of Washington, Spokane, Washington (K.R.T.). 13. University Hospital of Würzburg, Würzburg, Germany (C.W.). 14. Northwest Kidney Centers, Seattle, Washington (K.G.W.). 15. MAGIC Evidence Ecosystem Foundation, McMaster University, Hamilton, Ontario, Canada (L.L.). 16. College of Medicine and Public Health, Flinders University, and Cochrane Kidney and Transplant, Adelaide, Australia (J.C.C.). 17. School of Public Health, The University of Sydney, and Cochrane Kidney and Transplant, Sydney, Australia (D.J.T., M.H.). 18. University of Calgary, Calgary, Alberta, Canada (M.T.). 19. KDIGO, Brussels, Belgium (M.C., A.E.). 20. Steno Diabetes Center and University of Copenhagen, Copenhagen, Denmark (P.R.). 21. University of Washington, Kidney Research Institute, Seattle, Washington (I.H.D.). 22. Diabetes Research Centre, University of Leicester, and Leicester General Hospital, Leicester, United Kingdom (K.K.).
Abstract
DESCRIPTION: The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed a clinical practice guideline in 2020 for the management of patients with diabetes and chronic kidney disease (CKD). METHODS: The KDIGO Work Group (WG) was tasked with developing the guideline for diabetes management in CKD. It defined the scope of the guideline, gathered evidence, determined systematic review topics, and graded evidence that had been summarized by an evidence review team. The English-language literature searches, which were initially done through October 2018, were updated in February 2020. The WG used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to appraise evidence and rate the strength of the recommendations. Expert judgment was used to develop consensus practice points supplementary to the evidence-based graded recommendations. The guideline document underwent open public review. Comments from various stakeholders, subject matter experts, and industry and national organizations were considered before the document was finalized. RECOMMENDATIONS: The guideline includes 12 recommendations and 48 practice points for clinicians caring for patients with diabetes and CKD. This synopsis focuses on the key recommendations pertinent to the following issues: comprehensive care needs, glycemic monitoring and targets, lifestyle interventions, antihyperglycemic therapies, and educational and integrated care approaches.
DESCRIPTION: The Kidney Disease: Improving Global Outcomes (KDIGO) organization developed a clinical practice guideline in 2020 for the management of patients with diabetes and chronic kidney disease (CKD). METHODS: The KDIGO Work Group (WG) was tasked with developing the guideline for diabetes management in CKD. It defined the scope of the guideline, gathered evidence, determined systematic review topics, and graded evidence that had been summarized by an evidence review team. The English-language literature searches, which were initially done through October 2018, were updated in February 2020. The WG used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to appraise evidence and rate the strength of the recommendations. Expert judgment was used to develop consensus practice points supplementary to the evidence-based graded recommendations. The guideline document underwent open public review. Comments from various stakeholders, subject matter experts, and industry and national organizations were considered before the document was finalized. RECOMMENDATIONS: The guideline includes 12 recommendations and 48 practice points for clinicians caring for patients with diabetes and CKD. This synopsis focuses on the key recommendations pertinent to the following issues: comprehensive care needs, glycemic monitoring and targets, lifestyle interventions, antihyperglycemic therapies, and educational and integrated care approaches.
Authors: Martin Gritter; Rosa D Wouda; Stanley M H Yeung; Michiel L A Wieërs; Frank Geurts; Maria A J de Ridder; Christian R B Ramakers; Liffert Vogt; Martin H de Borst; Joris I Rotmans; Ewout J Hoorn Journal: J Am Soc Nephrol Date: 2022-05-24 Impact factor: 14.978
Authors: Aimin Yang; Hongjiang Wu; Eric S H Lau; Xinge Zhang; Mai Shi; Baoqi Fan; Ronald C W Ma; Alice P S Kong; Andrea O Y Luk; Juliana C N Chan; Elaine Chow Journal: Lancet Reg Health West Pac Date: 2022-06-24
Authors: José Gerardo González-González; Ricardo Cesar Solis; Alejandro Díaz González-Colmenero; Karina Raygoza-Cortez; Pablo J Moreno-Peña; Alicia L Sánchez; Rozalina G McCoy; Naykky Singh Ospina; Spyridoula Maraka; Juan P Brito; René Rodriguez-Gutierrez Journal: Diabetes Res Clin Pract Date: 2022-03-02 Impact factor: 8.180